JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 116 filers reported holding JOUNCE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.46 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $206,000 | +139.5% | 24,611 | +111.9% | 0.03% | +130.8% |
| Q3 2021 | $86,000 | +4.9% | 11,616 | -3.7% | 0.01% | +8.3% |
| Q2 2021 | $82,000 | -34.4% | 12,067 | -0.8% | 0.01% | -45.5% |
| Q1 2021 | $125,000 | +47.1% | 12,159 | 0.0% | 0.02% | +46.7% |
| Q4 2020 | $85,000 | -19.0% | 12,159 | -5.1% | 0.02% | -34.8% |
| Q3 2020 | $105,000 | +20.7% | 12,816 | +1.3% | 0.02% | +9.5% |
| Q2 2020 | $87,000 | – | 12,656 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $22,527,000 | 93.16% |
| TRV GP III, LLC | 1,148,780 | $9,592,000 | 2.40% |
| Deep Track Capital, LP | 4,000,000 | $33,400,000 | 2.36% |
| Ally Bridge Group (NY) LLC | 575,000 | $4,801,000 | 1.68% |
| Logos Global Management LP | 1,350,000 | $11,273,000 | 1.16% |
| PFM Health Sciences, LP | 3,972,868 | $33,173,000 | 1.13% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 245,829 | $2,053,000 | 0.83% |
| Yorktown Management & Research Co Inc | 137,300 | $1,146,000 | 0.77% |
| Sofinnova Investments, Inc. | 1,582,777 | $13,216,000 | 0.77% |
| ACUTA CAPITAL PARTNERS, LLC | 127,500 | $1,065,000 | 0.45% |